Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

This study has been completed.
Information provided by:
Luitpold Pharmaceuticals Identifier:
First received: February 23, 2011
Last updated: July 8, 2011
Last verified: July 2011

February 23, 2011
July 8, 2011
March 2006
July 2007   (final data collection date for primary outcome measure)
International Restless Legs Syndrome (IRLS) Total Score [ Time Frame: Change from Baseline to Day 28 ] [ Designated as safety issue: No ]
The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.
Same as current
Complete list of historical versions of study NCT01382901 on Archive Site
Not Provided
Safety Evaluations for All Reported Participants to Include: Adverse Events and Serious Adverse Events [ Time Frame: Day of initial treatment with study drug through completion of Treatment Phase of the study (Day 56) or 28 days after last treatment, whichever was later. ] [ Designated as safety issue: Yes ]
All safety analyses were performed using the Safety Population, defined as all subjects who received at least 1 dose of study drug.
Not Provided
Not Provided
Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)

Not Provided
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Restless Legs Syndrome (RLS)
  • Drug: Ferric Carboxymaltose (FCM)
    Other Name: VIT-45
  • Drug: Placebo
  • Experimental: Intravenous (IV) Iron
    Intervention: Drug: Ferric Carboxymaltose (FCM)
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2007
July 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects > or = to 18 years old, and able to give informed consent to the study.
  • RLS signs and symptoms affirming diagnosis. The IRLS Diagnostic Criteria for RLS must be met.
  • Subjects have RLS symptoms > or = to 5 nights per week for at least the past 3 months.
  • A baseline score > or = to 15 on the IRLS Rating Scale.
  • At least one leg with an average baseline Periodic Leg Movement while asleep (PLMS) > or = to 15 movements per hour and at least 3 days of baseline PLMS data is measurable in each leg.
  • Subjects on anti-depressants, sleep medications, dopamine agonists, benzodiazepines, narcotics or other RLS treatments must be off therapy at least one week or 5 half lives, whichever is longer before any baseline RLS assessments and PLM measurements are obtained.
  • Subject has regular sleep hours between 9 p.m. and 9 a.m.
  • Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control.

Exclusion Criteria:

  • RLS 2° to other CNS disease or injury. Such disorders include peripheral neuropathy, neurodegenerative disorders, and multiple sclerosis.
  • RLS 2° to Chronic Kidney Disease.
  • Any pain related or sleep related disorders (e.g. sleep apnea) which may confound the outcome measures.
  • History of neuroleptic akathisia.
  • Oral iron use (including multivitamins with iron) after screening.
  • Parenteral iron use within 4 weeks prior to screening.
  • Parenteral iron use > 125 mg per week within 4 to 8 weeks prior to screening.
  • History of > or = to 10 blood transfusions in the past 2 years.
  • Anticipated need for blood transfusion during the study.
  • Known hypersensitivity reaction to any component to FCM.
  • Previously participated in an FCM clinical trial.
  • Chronic or serious active severe infection.
  • Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for > 5 years).
  • Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).
  • Receiving prescription medication for the treatment of bronchospasm.
  • Pregnant or lactating women.
  • Severe peripheral vascular disease with significant skin changes.
  • Seizure disorder currently being treated with medication.
  • Baseline ferritin > 300 ng/mL.
  • Baseline TSAT > or = to 45%.
  • History of hemochromatosis or hemosiderosis or other iron storage disorders.
  • AST or ALT greater than the upper limit of normal.
  • Hemoglobin greater than the upper limit of normal.
  • Calcium or phosphorous outside the normal range.
  • Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis.
  • Known positive HIV-1/HIV-2 antibodies (anti-HIV).
  • Received an investigational drug within 30 days before randomization.
  • Chronic alcohol or drug abuse within the past 6 months.
  • Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) III or IV, or poorly controlled hypertension according to the judgment of the investigator.
  • Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.
  • Subject unable to comply with study requirements.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Luitpold Pharmaceuticals
Not Provided
Not Provided
Luitpold Pharmaceuticals
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP